{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/prostatitis-acute/prescribing-information/trimethoprim/","result":{"pageContext":{"chapter":{"id":"6aee14ab-550d-5bdd-b0e4-d2febce26f7a","slug":"trimethoprim","fullItemName":"Trimethoprim","depth":2,"htmlHeader":"<!-- begin field 3bfe8657-b492-4682-8be8-aa1700ab174a --><h2>Trimethoprim</h2><!-- end field 3bfe8657-b492-4682-8be8-aa1700ab174a -->","summary":"","htmlStringContent":"<!-- begin item 64012dd7-a14a-4019-88b6-aa1700ab16e7 --><!-- end item 64012dd7-a14a-4019-88b6-aa1700ab16e7 -->","topic":{"id":"73f0b35c-c49b-5f10-bb40-54ecdda0c994","topicId":"e7655eee-79f9-435e-b34e-7e3dc9576eb5","topicName":"Prostatitis - acute","slug":"prostatitis-acute","lastRevised":"Last revised in November 2020","chapters":[{"id":"8803a04f-6c62-5033-ac75-2e0987df1dd9","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"23265380-0c8c-51f6-984e-87cbf6e27684","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7f11e55f-ca93-5c30-86f8-fa21b370c650","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"aa21e1cb-1af6-5deb-b54b-9cb7a12a8a11","slug":"changes","fullItemName":"Changes"},{"id":"bc4d0c33-79f0-5fe0-8655-d9dbf99bbcf5","slug":"update","fullItemName":"Update"}]},{"id":"e29f027b-46a8-5ac6-b1b7-d063f673588e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"e0a59bba-34f6-512a-b3f6-19ba509165b0","slug":"goals","fullItemName":"Goals"},{"id":"b99f36b6-4383-55b0-8d6f-72dfeed4d249","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0629bcf7-67ce-5175-893c-bb0e770c16c1","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6da14859-d882-5bd2-b686-021dc2ab43ca","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"90fb5a5f-3ae5-53d9-b871-bf93c899f97c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a78a1b88-9559-551a-880f-736efedb2497","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c8ae728c-472f-509a-add8-39034e05aff0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"816a1fba-211e-520e-87c1-c47a23e06dd3","slug":"definition","fullItemName":"Definition"},{"id":"42efdea9-f709-5243-8b5c-a2b75dbbba5f","slug":"causes","fullItemName":"Causes"},{"id":"9713a2ac-cc24-5443-9756-3e59fbcf65b8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d981ad36-33da-56db-bb45-f12d69fe5543","slug":"prognosis","fullItemName":"Prognosis"},{"id":"5b0439a7-9599-542f-b2b2-51d20cc566f2","slug":"complications","fullItemName":"Complications"}]},{"id":"6553966d-798f-5d17-bcd0-6f62f2f8b5bd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d539bec4-2427-585f-a83c-db984fc0d801","slug":"suspecting-acute-prostatitis","fullItemName":"Suspecting acute prostatitis"},{"id":"d1e691e6-d634-508e-a5c1-62018b5b24be","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"2e7dc7c5-dc32-59bf-9021-54b838ce5a9b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"398acafd-0ba3-5cf1-8c9c-8d2ccca863ae","fullItemName":"Management","slug":"management","subChapters":[{"id":"8c56415b-f5bc-5fc1-b859-13b369ee963d","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"50977f3d-5737-50f5-9c23-c4a03b4539cf","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6f0cb41-8824-5f6b-9b63-19a56232237a","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"161382aa-bad2-5c17-9d1c-59f978dd6a83","slug":"ofloxacin","fullItemName":"Ofloxacin"},{"id":"6aee14ab-550d-5bdd-b0e4-d2febce26f7a","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"7fc380fc-24a6-5224-9d35-019f77e2d24e","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"fc84b330-890f-5ebf-b2cd-5724765b85a8","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole"}]},{"id":"c4981733-d5d6-5190-b43d-7cdee7ac825c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"137ffbc9-e5c4-5f58-bfc1-4d3afb883356","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5f07d427-7c9b-521d-ba7a-1a7bc564f48d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"05f5c8e4-6073-506c-909a-cef5c3cf622c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"63ca9076-27d4-5254-9eda-bcbb43177d95","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ff474396-1f31-58cd-b153-976c3894cafd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"be6b66c2-c9cc-5d52-99dd-044e49dadfb0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9b5aeabb-1902-5659-8e0b-625f567b86e0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"50977f3d-5737-50f5-9c23-c4a03b4539cf","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"264e457a-7bdf-5eba-8ae1-cd7a4d16fa1e","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 54c5548a-848c-4c23-bf16-aa1700ab95c0 --><h3>Cautions and contraindications</h3><!-- end field 54c5548a-848c-4c23-bf16-aa1700ab95c0 -->","summary":"","htmlStringContent":"<!-- begin item 76cc96e7-84d6-464a-9bb7-aa1700ab958f --><!-- begin field cb10c711-39dd-450b-b2d8-aa1700ab95c0 --><ul><li><strong>Do not prescribe trimethoprim to people with:</strong><ul><li>Severe hepatic insufficiency, or severe renal insufficiency.</li><li>Megaloblastic anaemia or other blood dyscrasias.</li></ul></li><li><strong>Prescribe trimethoprim with caution to people:</strong><ul><li>With impaired renal function.</li><li>With hyperkalaemia, or taking medication that is known to cause hyperkalaemia.</li><li>With acute porphyrias.</li><li>Predisposed to folate deficiency — because of the potential anti-folate effect of trimethoprim, there is a risk of further exacerbating folate deficiency in people who are folate deficient, or who are predisposed to folate deficiency (for example elderly people), or who are taking folate antagonists.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field cb10c711-39dd-450b-b2d8-aa1700ab95c0 --><!-- end item 76cc96e7-84d6-464a-9bb7-aa1700ab958f -->","subChapters":[]},{"id":"bcdac406-ebd3-50fd-9c4b-f6506baf1542","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 0958fd2a-0bbe-475c-b262-aa1700aba40b --><h3>Adverse effects</h3><!-- end field 0958fd2a-0bbe-475c-b262-aa1700aba40b -->","summary":"","htmlStringContent":"<!-- begin item 98ea1a28-76c0-4a12-b9ba-aa1700aba3e8 --><!-- begin field afa5b55c-a88f-413a-bfe6-aa1700aba40b --><ul><li><strong>Blood disorders</strong> — leucopenia, megaloblastic anaemia, thrombocytopenia, agranulocytosis, hyperkalaemia (particularly in the elderly and in HIV patients), methaemoglobinaemia.</li><li><strong>Gastrointestinal</strong> — diarrhoea, nausea, vomiting, glossitis.</li><li><strong>Nervous system</strong> — headache (common).<ul><li><strong>Very rarely: </strong>dyskinesias, tremor, ataxia, dizziness, lethargy, aseptic meningitis (frequency unknown).</li></ul></li><li><strong>Skin</strong> — urticaria, skin rashes (common).<ul><li><strong>Rarely: </strong>photosensitivity, exfoliative dermatitis, fixed drug eruption, erythema multiforme, erythema nodusum, Stevens-Johnson Syndrome, toxic epidermal necrolysis, bullous dermatitis, purpura, angioedema.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Anaphylaxis.</li><li>Hypoglycaemia.</li><li>Liver enzyme disturbances, cholestatic jaundice.</li><li>Myalgia.</li><li>Raised serum creatinine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field afa5b55c-a88f-413a-bfe6-aa1700aba40b --><!-- end item 98ea1a28-76c0-4a12-b9ba-aa1700aba3e8 -->","subChapters":[]},{"id":"92f81213-27b9-576b-8f89-09eb024964e1","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field f2fe1204-3fe4-45c1-bc2a-aa1700abb422 --><h3>Drug interactions</h3><!-- end field f2fe1204-3fe4-45c1-bc2a-aa1700abb422 -->","summary":"","htmlStringContent":"<!-- begin item a8d50ab7-0f93-4b8e-b3aa-aa1700abb3fc --><!-- begin field 7c491dcb-5dfe-4a46-91f7-aa1700abb422 --><ul><li><strong>Angiotensin-converting enzyme (ACE) inhibitors and </strong><strong>angiotensin-II receptor antagonists (</strong><strong>AIIRAs)</strong> — there may be an increased risk of hyperkalaemia with the concurrent use of these drugs and trimethoprim. Monitor potassium concentrations. </li><li><strong>Azathioprine and mercaptopurine </strong>— increased risk of haematological toxicity in people who have had a renal transplant. However, the combination is commonly used in practice. Monitor the full blood count routinely.</li><li><strong>Ciclosporin </strong>— serum creatinine levels may be increased. Possible increased risk of nephrotoxicity. Monitor ciclosporin concentrations and effect on renal function closely.</li><li><strong>Coumarins (warfarin) </strong>— the anticoagulant effect of coumarins may be potentiated. Monitor international normalised ratio (INR) and adjust dose accordingly.</li><li><strong>Digoxin</strong> — digoxin levels may be increased in the elderly if taken with trimethoprim. Monitor for digoxin adverse effects, and adjust dose accordingly.</li><li><strong>Diuretics </strong>— hyperkalaemia may be exacerbated by concurrent administration of diuretics, particularly potassium sparing diuretics and/or thiazide diuretics and eplerenone.</li><li><strong>Methotrexate (a folate antagonist) </strong>— there is an increased risk of haematologic adverse effects. Several cases of bone marrow suppression have been reported (some fatal). Full blood count should be monitored routinely.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of trimethoprim.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>. </li></ul></li><li><strong>Phenytoin </strong>— phenytoin levels may be increased if taken with trimethoprim. Monitor phenytoin levels and adjust dose accordingly.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field 7c491dcb-5dfe-4a46-91f7-aa1700abb422 --><!-- end item a8d50ab7-0f93-4b8e-b3aa-aa1700abb3fc -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}